Dynepo (epoetin delta)
- Region
- 🇪🇺 EU
- Active substance
- epoetin delta
- Company
- Shire Pharmaceutical Contracts Limited
- Status
- Withdrawn
- Therapeutic area
- Kidney Failure, Chronic; Anemia
- EU approval
- Mon 18 Mar 2002
- Application
- EMEA/H/C/000372
- ATC
- B03XA
- Official record
- www.ema.europa.eu
Indication
Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. It may be used in patients on dialysis and in patients not on dialysis.
Regulatory milestones
No milestones recorded in the last year.
Follow Dynepo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.